The Use of Magnetic Resonance Imaging-guided Focused Ultrasound in Movement Disorders—A Review
Abstract
Overview
The use of surgical treatments for movement disorders has been well established for several decades, with a strong focus, in the past, on ablative lesioning procedures and, more recently, deep brain stimulation. Magnetic resonance imaging (MRI)-guided focused ultrasound (MRgFUS) is emerging as a newly recognized surgical technique for the treatment of various movement disorders. The most robust data, demonstrating safety and efficacy of MRgFUS, have been published in trials directed at treatment of essential tremor (ET); however, many trials are underway to define its role in other movement disorders, such as Parkinson’s disease with preliminary results echoing those from studies in ET. The full potential for use of MRgFUS, both in the field of movement disorders and beyond, is only beginning to be explored.
Keywords
Essential tremor, Parkinson’s disease, tremor, thalamotomy, focused ultrasound
Article Information
Disclosure
Lauren S Talman and Binit B Shah have nothing to declare in relation to this article. No funding was received in the publication of this article.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Correspondence
Binit B Shah, MD. PO Box 800394, McKim Hall 2nd Floor, Charlottesville, VA 22908, US. E: binitshah@virginia.edu
Access
This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.
Received
2017-05-19T00:00:00
Further Resources
Trending Topic
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle Demeestere and Sarah Gorey’s editorial on the 2025 European Stroke Organisation Conference (ESOC), which […]
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
The surge in social media use seems to have become a sign of our times. Social media has ramified into not only our personal lives but, importantly, also our professional lives and will continue to do so in the future.1–4 ...
Myoclonus is defined as a sudden, brief, lightning-like muscle contraction.1 It was first described by Friedreich in 1881 when he detailed sharp jerks involving the bulk of a full muscle without marked limb or joint movement and called it paramyoclonus multiplex.2 ...
It has been nearly 160 years since Friedreich’s ataxia (FRDA) was clinically recognized and described1 and 25 years since the FXN gene was discovered.2 Despite this, there are still no approved therapies for FRDA. FRDA is an autosomal, recessively inherited, neurodegenerative ...
Welcome to the spring edition of US Neurology. This journal aims to address topical subjects in the field of neurology to stimulate discussion focused on these issues. Articles have been chosen for their evaluation of current practices and research and ...
Welcome to the latest edition of European Neurological Review, which features a diverse range of topical articles covering a variety of therapeutic areas. This edition begins with a timely editorial from Milonas on recent advances in multiple sclerosis (MS), which ...
The clostridial neurotoxins (CNTs) (tetanus toxin [TeNT] and seven serologically distinct botulinum neurotoxins [BoNT/A–BoNT/D]), are among the deadliest agents known. They are bacterial enzymes produced by anaerobic, spore-forming bacteria of the genus Clostridium. Each toxin is composed ...
Patients with spastic paresis often endure prolonged treatment regimens, where each journey is patient-specific and often difficult. Spasticity – defined as increased, involuntary, velocity-dependent muscle tone that causes resistance to movement – is a complex condition that often causes pain, contractures and ...
Multiple system atrophy (MSA) is a is an adult-onset, sporadic, progressive neurodegenerative disease characterized by a varying combination of parkinsonism, cerebellar ataxia, autonomic failure, and corticospinal dysfunction. Patients either have a predominance of parkinsonian symptoms (MSA-P) such that they are ...
Parkinson’s disease (PD) has been traditionally defined by the motor symptoms of bradykinesia, resting tremor, rigidity and postural instability;1 however, more recently, it has been recognized that neuropsychiatric symptoms such as psychosis, anxiety, depression, apathy, impulse control disorders and ...
Spastic paresis may be caused by a variety of conditions, including stroke, spinal cord injury, multiple sclerosis, retroviral and other infectious spinal cord disorders, cerebral palsy, traumatic brain injury and hereditary spastic paraplegia.1 The exact prevalence of spastic paresis (in ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
